Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases.
Elevated levels of nerve growth factor (NGF) have been detected in the bronchoalveolar lavage fluid of patients with asthma. However, the source of this enhanced mediator production is not known. Here, we investigate the production of NGF from a human airway epithelial cell line (A549). Under basal conditions, A549 cells generated NGF in a time-dependent fashion. However, basal release was significantly augmented in a concentration-dependent manner in cells treated with interleukin-1beta (IL-1beta) or tumour necrosis factor-alpha (TNF-alpha) and inhibited by dexamethasone. These data suggest that NGF released from structural cells may be an important target for the anti-inflammatory effects of steroids in asthma therapy.
Fox
A J
AJ
Novartis Institute for Medical Sciences, 5 Gower Place, WC1E 6BN, London, UK.
Patel
H J
HJ
Barnes
P J
PJ
Belvisi
M G
MG
D001249:Asthma / Q000188:drug therapy / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D008168:Lung / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D020932:Nerve Growth Factor / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone; D020932:Nerve Growth Factor